These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Effects of milrinone on contractility and cyclic adenosine monophosphate production induced by beta1- and beta2-adrenergic receptor activation in human myocardium. Carceles MD; Fuentes T; Aroca V; Lopez J; Hernández J Clin Ther; 2007 Aug; 29(8):1718-24. PubMed ID: 17919552 [TBL] [Abstract][Full Text] [Related]
8. Phosphodiesterase-5 Is Elevated in Failing Single Ventricle Myocardium and Affects Cardiomyocyte Remodeling In Vitro. Garcia AM; Nakano SJ; Karimpour-Fard A; Nunley K; Blain-Nelson P; Stafford NM; Stauffer BL; Sucharov CC; Miyamoto SD Circ Heart Fail; 2018 Sep; 11(9):e004571. PubMed ID: 30354365 [TBL] [Abstract][Full Text] [Related]
9. Comparative effects of R 80122, enoximone, and milrinone on left ventricular phosphodiesterase isoenzymes in vitro and on contractility of normal and stunned myocardium in vivo in dogs. Vandeplassche GM; Hermans CF; de Chaffoy de Courcelles DR; D'Aubioul JA; Wouters LJ; De Clerck FF J Cardiovasc Pharmacol; 1992 May; 19(5):714-22. PubMed ID: 1381769 [TBL] [Abstract][Full Text] [Related]
10. Pharmacy Support of a Pediatric Patient Receiving Milrinone at Home. Xue A; Dersch-Mills D; Tsang C; Greenway SC Can J Hosp Pharm; 2016; 69(5):415-419. PubMed ID: 27826160 [No Abstract] [Full Text] [Related]
11. Various phosphodiesterase activities in different regions of the heart alter the cardiac effects of nitric oxide. Demirel-Yilmaz E; Cenik B; Ozcan G; Derici MK J Cardiovasc Pharmacol; 2012 Sep; 60(3):283-92. PubMed ID: 22653417 [TBL] [Abstract][Full Text] [Related]
12. Differential expression of PDE5 in failing and nonfailing human myocardium. Shan X; Quaile MP; Monk JK; French B; Cappola TP; Margulies KB Circ Heart Fail; 2012 Jan; 5(1):79-86. PubMed ID: 22135403 [TBL] [Abstract][Full Text] [Related]
13. PDE3 inhibition in dilated cardiomyopathy. Movsesian M; Wever-Pinzon O; Vandeput F Curr Opin Pharmacol; 2011 Dec; 11(6):707-13. PubMed ID: 21962613 [TBL] [Abstract][Full Text] [Related]
14. Characterization of the phosphodiesterase inhibition by 2-(3-methoxy-5-methylsulfinyl-2-thienyl)-1H-imidazo-(4,5-c)-pyridine HCl and its sulfide- and sulfone derivatives in myocardial preparations from failing human hearts. Bethke T; Klimkiewicz A; Meyer W; Schumacher C; Schmitz W; Scholz H; Starbatty J; Wenzlaff H; Zimmermann W Arzneimittelforschung; 1995 Jul; 45(7):771-6. PubMed ID: 8573220 [TBL] [Abstract][Full Text] [Related]
15. Constitutive phosphodiesterase activity restricts spontaneous beating rate of cardiac pacemaker cells by suppressing local Ca2+ releases. Vinogradova TM; Sirenko S; Lyashkov AE; Younes A; Li Y; Zhu W; Yang D; Ruknudin AM; Spurgeon H; Lakatta EG Circ Res; 2008 Apr; 102(7):761-9. PubMed ID: 18276917 [TBL] [Abstract][Full Text] [Related]
16. Pharmacology of milrinone in neonates with persistent pulmonary hypertension of the newborn and suboptimal response to inhaled nitric oxide. McNamara PJ; Shivananda SP; Sahni M; Freeman D; Taddio A Pediatr Crit Care Med; 2013 Jan; 14(1):74-84. PubMed ID: 23132395 [TBL] [Abstract][Full Text] [Related]
17. Myocardial phosphodiesterases and regulation of cardiac contractility in health and cardiac disease. Osadchii OE Cardiovasc Drugs Ther; 2007 Jun; 21(3):171-94. PubMed ID: 17373584 [TBL] [Abstract][Full Text] [Related]
18. Catheterization diastolic pressures correlate with diastolic dyssynchrony in patients with single right ventricles. Stiver C; Gokhale J; Husain N; Nicholson L; Cordier J; Van Lente L; Holzer RJ; Cua CL Echocardiography; 2014 Mar; 31(3):370-4. PubMed ID: 24298988 [TBL] [Abstract][Full Text] [Related]
19. Use of milrinone to treat cardiac dysfunction in infants with pulmonary hypertension secondary to congenital diaphragmatic hernia: a review of six patients. Patel N Neonatology; 2012; 102(2):130-6. PubMed ID: 22710735 [TBL] [Abstract][Full Text] [Related]
20. New pharmacologic interventions to increase cardiac contractility: challenges and opportunities. Movsesian M Curr Opin Cardiol; 2015 May; 30(3):285-91. PubMed ID: 25807221 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]